icn pharmaceuticals lticn seeking acquisition icn pharmaceuticals 500 mln dlrs cash 150 billion dlrs credit intends buy pharmaceutical company chairman milan panic said companys annual meeting acquisition place 24 months the company billion dlrs acquisition today panic said adding we investigating number companies company studied possibly acquired friendly basis said panic intends seek board approval today repurchase mln icn common shares discussing possibility acquisition panic purchase icns current marketing capability sufficient support distribution companys products icns expectations market growth worldwide icns principal product ribavirin virazole drug marketed number countries broadbased antiviral company applications include treatment types hepatitis herpes influenza childhood diseases hemorrhagic fevers icn focus consirable investor attention recent months virazole undergone clinical trials treatment aidsrelated diseases panic today discuss drug regard aids food drug administration completes review data submitted company investigation drug conducted house subcommittee continuing subcommittee fda acknowledged conducting separate investigations determine icn witheld data fda adverse reactions drug virazole approved marketing us aerosol form treatment infection strikes infants called respiratory syncytial virus